Clinical trials / NCT06558799
NCT06558799Phase 2Terminated

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Study sponsor: NovoCure GmbH

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2026-02-23Actual
Enrollment · participants31Actual
Source updated2026-06-01Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

69 participants (planned)

+ After

31 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

31 Jan 2026

+ After

23 Feb 2026

Recruitment status changed

− Before

Active not recruiting

+ After

Terminated

Check registry source

· 2 fields changed

Primary completion date changed

− Before

Dec 2026

+ After

31 Jan 2026

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source